Access Dermatology

Breaking News

• Breaking News List »
• 2010 »
• February »

Ustekinumab improves quality of life in patients with moderate-severe psoriasis

A 76-week, phase III, randomized, double-blind, placebo-controlled study (PHOENIX 1) demonstrated the long-term safety and efficacy of ustekinumab 45 mg and 90 mg in 766 patients with moderate-severe psoriasis. This study reported on the health-related quality of life (HRQoL) of patients in this study as measured by the Dermatology Life Quality Index (DLQI) and Short-Form 36 (SF-36) questionnaire. At week 12, significantly more patients receiving ustekinumab achieved a normalized DLQI score (1 or less) versus placebo: 53.2, 52.4 and 6% in the ustekinumab 45 mg, 90 mg and placebo groups, respectively (both P < 0.001). Improvement was also seen on both the Physical and Mental Component Scores of the SF-36 in ...